

Marion David, Davide Monteferrario, Gaëlle Saviane, Caroline Jeanneau, Irène Marchetti, Coralie Dupont, Céline Dumont, Jason Fontenot, Maurus de la Rosa,* and David Fenard*

*Co-senior authors

Sangamo Therapeutics France, Allée de la Nertière, Les Cardoulines HT1, 06560 VALBONNE, France

Introduction


- After antigen engagement, B cells, key effectors of adaptive immune response, differentiate into plasmablast/plasma cells.
- The long-lived plasma cells can survive for decades in the bone marrow and secrete large quantities of antibodies.
- Recent developments around precise editing technologies open the possibility of engineering plasmablast/plasma cells to act as autologous cell factories, capable of delivering sustained and high doses of therapeutic proteins.
- In this study, using a serum-free Good Manufacturing Practice (GMP)-compatible medium, we developed optimal culture conditions for B cell differentiation into plasmablast/plasma cells in vitro and site-specific transgene insertion into distinct loci. For that, B cell engineering was performed by combining electroporation of zinc finger nuclease (ZFN) mRNA with adeno-associated virus type 6 (AAV6) donor DNA template delivery.
- As a proof of concept, B cells were engineered for the expression of the human factor IX (FIX)-Padua. FIX deficiency is the leading cause of hemophilia B, a genetic disease characterized by blood clotting defects.

Methods

Autologous engineered B-cell therapy concept

Patient-derived B cells can be engineered to express a therapeutic protein, expanded and differentiated into plasmablasts/plasma cells ex vivo.

Upon re-infusion, cells are expected to engraft and serve as an in vivo source for sustained circulation of the therapeutic factor.




B-cell engineering using ZFN/AAV6 technology

The ZFN mRNA electroporation generates a double-strand break on a targeted gene locus.

Next, the transduction with an AAV6 vector, harboring the transgene flanked by genomic sequences homologous to the target site, triggers the insertion of the transgene into the targeted locus by homologous recombination.¹

The target genes are a safe harbor (*AAVS1*) and silent genes (*TRAC*, *CCR5*).



ELISA, enzyme-linked immunosorbent assay.

Acknowledgments


We thank Sangamo's collaborators, in particular the animal care facility.

Author Disclosures

All authors are or were employees of Sangamo Therapeutics

Results


Efficient B cell differentiation was achieved in vitro using a GMP-compatible serum-free medium



(A) Schematic showing overview of the in vitro B cell culture protocol. The first week, B cells were expanded in presence of sCD40L, ODN, and IL-2, IL-10, and IL-15 cocktail.² The second week, B cells were continuously expanded or differentiated. Every 2-4 days, cell expansion fold and cell viability were monitored (B and C).


IL, interleukin; ODN, oligodeoxynucleotide; sCD40L, soluble CD40 ligand.

The B cell culture protocol promotes differentiation mainly in plasmablasts and to a lesser extent in plasma cells




(A) Monitoring of plasmablast (CD38+CD138-) and plasma cell (CD38+CD138+) production in expansion (EXP, n=11) versus differentiation (DIF, n=15) protocol. (B) Cells were stained for multiple B cell differentiation markers (CD38+, CD138+, CD20-, CD27+, XBPI+, and BLIMP-1+). Gray and pink curves correspond respectively to B cells obtained at day 0 or day 14 in DIF protocol.

The use of ZFN/AAV6 editing technology allows highly efficient engineering of B cells at multiple genomic loci



Cells were electroporated with locus-specific ZFN mRNA followed by AAV6 transduction using the indicated vectors expressing green fluorescent protein (GFP) (A) or human FIX-Padua (B). Cells were analyzed 4 days post editing to quantify indels associated with GFP-engineered B cells (C) or FIX-engineered B cells (D). (E) Supernatants were collected 1 day post seeding, and total FIX antigen was quantified by ELISA for FIX-engineered B cells.


An in vivo NSG/Tm mouse model was used for optimal engraftment of differentiated/engineered human B cells



In vivo mouse model for differentiated human B cell engraftment. Memory T (Tm) cells were administered via the intraperitoneal (IP) route into 8-week-old NSG mice.³ 2 weeks prior to intravenous (IV) administration of donor-matched, differentiated, and engineered B cells (FIX-Padua cassette into the *TRAC* locus). Every week post injection, blood was drawn for monitoring of human immunoglobulins (Hulg) and FIX-Padua production. At day 41, mice were euthanized, and spleen and bone marrow were recovered to evaluate the efficiency of human B cell engraftment.


Eng, engineered.

FIX-engineered B cells engrafted in mice are strongly differentiated in plasma cells and plasmablasts




(A) The percentage of human plasmablasts (PB) and plasma cells (PC) was evaluated in organs after labeling of CD38 and CD138 markers and flow cytometry analysis. (B) Phenotype of engrafted B cells. Monitoring of PB (CD38+CD138-), PC (CD38+CD138+), naive B cells (CD27-IgD+), and other CD19+ B cells just after B cell isolation (in vitro day 0), differentiation protocol (in vitro day 14), or in vivo in murine spleen and bone marrow (day 41 post injection).

Human plasma cells are highly engrafted in mouse bone marrow



Phenotyping (day 41) of engrafted human B cells by monitoring the expression of CD20 (A), CD27 (B), BLIMP-1 (C), or XBPI (D). As expected, human B cells engrafted in the bone marrow (Bone M) are mainly plasma cells (CD20-CD27+BLIMP-1+XBPI+).

B cells engineered with ZFN/AAV6 technology secrete a therapeutical level of human FIX-Padua in vivo



Every week post injection, blood was drawn from NSG mice, and presence of human immunoglobulins (Ig) and FIX-Padua was quantified. (A) High levels of circulating human IgG and IgM in mouse blood reflect the engraftment of differentiated human B cells. (B) Efficient secretion of human FIX-Padua from FIX-engineered B cells in vivo. A targeted integration (TI) efficiency ranging from 5% to 20% allows a therapeutic FIX expression from 5% to 15% of normal wild-type FIX, respectively.

HemB, hemophilia B.

Conclusions

- In summary, we demonstrated that ZFN mRNA combined with rAAV6 donor DNA allows efficient site-specific insertion of human FIX transgene into the B cell *TRAC* locus, resulting in therapeutic levels of FIX-Padua expression in vivo.
- This study highlights the therapeutic potential of engineering B cells as a new technological platform to treat a variety of protein deficiencies, blood disorders, infectious diseases, or cancers.

References

1. Wang J, et al. *Nat Biotechnol.* 2015;33(12):1256-1263.
2. Hung KL, et al. *Mol Ther.* 2018;26(2):456-467.
3. Ishikawa Y, et al. *Eur J Immunol.* 2014;44:3453-3463.